Stay current with all the latest and breaking news about Novo Nordisk, compare headlines and perspectives between news sources on stories happening today. In total, 32 stories have been published about Novo Nordisk which Ground News has aggregated in the past 3 months.
CNBC
•Novo Nordisk shares shrug off concerns over study linking weight loss drugs to rare eye condition
View summary
Investor's Business Daily
•Futures: Rivian Skyrockets, Nvidia Extends Rebound
View summary
CNBC
•Novo Nordisk's Wegovy weight loss drug approved in China
View summary
Reuters
•Wegovy-maker Novo Nordisk to spend $4.1 billion to boost US manufacturing
View summary
CNBC
•Novo Nordisk to build $4.1 billion North Carolina facility to boost output of Wegovy, Ozempic
View summary
NBC News
•'Novo Nordisk is ripping off the American people,' Bernie Sanders says of Ozempic and Wegovy costs
View summary
CNBC
•Healthy Returns: More U.S. employers are now covering GLP-1s for weight loss
View summary
Ars Technica
•Drugmaker to testify on why weight-loss drugs cost 15x more in the US
View summary
Investor's Business Daily
•Novo Nordisk (NVO) and Eli Lilly (LLY) have seen huge gains in recent years
View summary
The Motley Fool
•Three Motley Fool contributors think Eli Lilly, Novo Nordisk, and Vertex are growth stocks you can buy right now
View summary
Gizmodo
•Novo Nordisk CEO Lars Jrgensen agrees to testify before Sen. Sanders' Senate committee on Ozempic and Wegovy
View summary
The Motley Fool
•Got $200? 2 Healthcare Stocks to Buy and Hold Forever.
View summary
Reuters
•Second Chinese drugmaker seeks approval for Ozempic generic
View summary
VOA
•Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China
View summary
Investor's Business Daily
•Dow Jones Falls As Fed Official Says This, But Nasdaq Leads; GameStop Soars Amid Roaring Kitty Bet
View summary
The Motley Fool
•Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
View summary
Reuters
•Wegovy maker Novo Nordisk sues nine spas, clinics and pharmacies over copycat drugs
View summary
Reuters
•Novo blames US health system after criticism over Wegovy price, Bloomberg reports
View summary
CNBC
•This new weight loss drug ETF bets big on two of the industry's leading players
View summary
Reuters
•European shares to hit pause before rising again in 2025: Reuters poll
View summary